JOURNEY MEDICAL CORPDERM
ASignal's systematic analysis rates DERM as Neutral.
Reflects the latest available analysis · analyzed Oct 15, 2026
The case on DERM
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (23.3% YoY)
- High gross margin (65.45%) indicating pricing power
- Low debt-to-equity ratio (0.80x) within moderate range
- Positive free cash flow trend expected as cash position exceeds debt
- Negative operating cash flow (-$7.49M)
- Negative free cash flow (-$5.46M)
- Negative return on equity (-23.77%)
- Negative profit margin (-8.95%)
- Overvalued based on EV/EBITDA (122.47x)
- Bearish technical momentum (price below SMA20 and SMA50)
See the full verdict on DERM
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes DERM
Most investors never get a second opinion, let alone several. ASignal runs DERM past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.